<SEC-DOCUMENT>0001070081-21-000015.txt : 20210504
<SEC-HEADER>0001070081-21-000015.hdr.sgml : 20210504
<ACCEPTANCE-DATETIME>20210504160507
ACCESSION NUMBER:		0001070081-21-000015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210504
DATE AS OF CHANGE:		20210504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		21888350

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ptct-20210504x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/4/2021 7:55:44 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 0ead7867-6a1d-4f26-8dea-8d189b0d05de -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20210504" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityCentralIndexKey" id="Tc_hvxiUsZoi0yLmHJ1MxmXiQ_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:AmendmentFlag" id="Tc_XwA0o76Dgk-CxNnYvctUYQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20210504.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1c2b8121_8120_4d2c_bf9a_3bd62a26e6df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:DocumentType" id="Narr_lzL2h9TWUEm8hxyEovJcig"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_7t0mWQXXlEykqLU0U418Kw"><b style="font-size:9pt;font-weight:bold;">May 4, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityRegistrantName" id="Narr_7GZgWUYXGkCYsHTTuaJ-zw"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_6yLoaUuFqkeoL-Ka22_i2A_2_0"></a><a id="Tc_4NayIUFZhECIeM_SezD4kA_2_2"></a><a id="Tc_TSghAgoYRkWsxrCSopyBug_2_4"></a><a id="Tc_ieItPCVoGEuX2AspWpoxcA_3_0"></a><a id="Tc_YwltUHUmW0OHJq_Bjgt8Rg_3_2"></a><a id="Tc__j5bDwKovkaehS7MvAayZg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_fFLHK7B6JUC7j7TDsHn_4A_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityFileNumber" id="Tc_kyw_hDQNLEuESNNYL5o0TA_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityTaxIdentificationNumber" id="Tc_iC7onP3bMkyfglZfj9Tveg_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc__xgtGWoNA0WzCaOmPkKE-Q_2_0"></a><a id="Tc_G0mEKYt1b0qlRwkfa21vTA_3_0"></a><a id="Tc_Et5Hc8_Eo0a7ZsZiyzB06g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityAddressAddressLine1" id="Tc_iEdivVLIBEa0I6_TZStJ8A_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityAddressCityOrTown" id="Narr_HKpNm0mI2EetlaK9jIfXUA"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityAddressStateOrProvince" id="Narr_Dc12wex61UW_HiH6zFwLOQ"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:EntityAddressPostalZipCode" id="Tc_LDtiFDk4QUaDSRGM_983pQ_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:CityAreaCode" id="Narr_-DEPeNK_MkGXked7N-Y2xQ"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:LocalPhoneNumber" id="Narr_MRVbwu1G-UKKz4moZrjeFw"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_98rgxFR0j06oWmIpB75hOA"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_09Zp2f0NzEG2vWZWB2V42g"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_i9pgC4iVW0OPmzE3WJMU9g"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_bhlkJ-xcBEKYEBNGm_e8ig"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_oANFUkGHpkGd2sJXduTlXQ_1_0"></a><a id="Tc_ARpWHtnKikGwfhEjPAzIIw_1_2"></a><a id="Tc_Abh1hldZx0qHNswPPfvmpg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:Security12bTitle" id="Tc_iQ-xtfmqcE2u5TetlNgPnQ_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" name="dei:TradingSymbol" id="Tc_RcPUcIO0_0Ses93Lb_3NCQ_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_eC0ZZOI3Z0ifJJ375MhDyg_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_ftZPt3nRo0ChTVt4-XY4Hg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0005bee0_2063_49b7_b5e6_ffad2cbfbe2d"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.02.&#160;Results of Operations and Financial Condition.</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On May 4, 2021, PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March 31, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K (this &quot;Report&quot;) and is incorporated by reference into this Item&#160;2.02.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f1f1883b_0361_4efe_b726_ccb5a9303f84"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;7.01.&#160;Regulation FD Disclosure.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company will host a conference call on May 4, 2021 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended March 31, 2021, as well as other corporate highlights and updates.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit&#160;99.1 hereto.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00c374eb_0118_4061_8a8d_70ded480bd97"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptct-20210504ex9919ca02a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release, dated May 4, 2021 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page&#160;from this Current Report on Form&#160;8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_63e2b05b_6c05_4329_ae5b_8f5aebdbaf1a"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 4, 2021</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptct-20210504ex9919ca02a.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/4/2021 07:55:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:15.0pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:84.3pt;"><img src="ptct-20210504ex9919ca02a001.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">PTC Therapeutics Provides a Corporate Update and <br>Reports First Quarter 2021 Financial Results<br></b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Total net revenue of $118 million; 73% increase over first quarter 2020 -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- DMD franchise net product revenue of $90 million; 32% increase over first quarter 2020 &#8211;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- PTC has clinical trials ongoing in multiple disease areas, three of which are registration-directed studies - </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., May 4, 2021</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;Overall PTC has had a strong performance this quarter through all aspects of the company from discovery to commercial revenue,&#8221; said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;I would like to highlight the continued strong growth of the DMD franchise which has had one of our largest quarterly revenues to date. The other key milestone was the positive preliminary results in our PTC518 Huntington&#8217;s disease program demonstrating dose dependent lowering of the HTT mRNA. Analogous to the SMA program we are now well positioned with a clear path for success.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key First Quarter and Other Corporate Updates:</b></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">The Duchenne muscular dystrophy (DMD) franchise had a total net product revenue of $90 million for Translarna&#8482; (ataluren) and Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) in the first quarter of 2021. This represents 32% growth over the first quarter of 2020 and one of PTC&#8217;s strongest quarterly commercial revenues to date.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Broader uptake due to new patients in existing geographies and geographic expansion drove Translarna growth. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza revenue growth was primarily due to increased new prescriptions, high compliance, and fewer discontinuations. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">In March 2021, the European Medicines Agency (EMA) approved Evrysdi&#8482; (risdiplam) in the European Union (EU). The first sale of Evrysdi in this region was recorded the following day, triggering a $20 million milestone payment to PTC. Evrysdi is a product of a collaboration between PTC, Roche and the SMA Foundation.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Preliminary results from the PTC518 Phase 1 healthy volunteer trial demonstrated dose-dependent reduction of Huntington mRNA beyond the 30-50% target.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">PTC received Gallup&#8217;s Don Clifton Strengths-Based Culture Award, which reflects the Company&#8217;s ongoing deep commitment to its employees.</font></div><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="background-color:#ffff00;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="background-color:#ffff00;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">First Quarter Clinical Updates:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">PTC has multiple clinical trials ongoing, three of which are registration-directed clinical studies: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The MIT-E Phase 2/3 trial with vatiquinone for mitochondrial epilepsy with data anticipated in the third quarter of 2022. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The MOVE-FA Phase 3 trial with vatiquinone for Friedreich ataxia with data anticipated in 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The FITE19 Phase 2/3 clinical trial for PTC299 in patients with COVID-19 with an expected data readout in the second half of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The second Bio-e compound, PTC857 healthy volunteer study was recently completed, and data will be communicated in the second quarter.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The registration-directed Phase 3 PTC923 phenylketonuria (PKU) trial, APHENITY, is expected to initiate in mid-2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The Committee for Medicinal Products for Human Use (CHMP) has requested a clock stop in the aromatic L-amino acid decarboxylase (AADC) deficiency review process to allow for completion of its pre-approval inspections, which were delayed due to COVID-19. The CHMP opinion is now anticipated in the third quarter of 2021. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Due to COVID-related surgical delays, the AADC-deficiency biologics license application submission to the U.S. Food and Drug Administration is anticipated to be delayed by at least one quarter.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:15.2pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">First Quarter 2021 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Total revenues were&#160;$117.9 million for the first quarter of 2021, compared to total revenues of $68.3 million for the first quarter of 2020, a 32% increase. Total revenue includes net product revenue of&#160;</font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">$91.3 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">&#160;and collaboration and royalty revenue of&#160;</font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">$26.7 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">&#160;in the first quarter of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Translarna net product revenues were $46.5 million for the first quarter of 2021, compared to $40.5 million for the first quarter of 2020. These results reflect an increase in net product sales in existing markets as well as continued geographic expansion into new territories.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Emflaza net product revenues were $43.5 million for the first quarter of 2021, compared to $27.5 million for the first quarter of 2020. These results reflect new patient prescriptions, high compliance, and fewer discontinuations.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Roche reported Evrysdi first quarter 2021 sales of approximately CHF 80 million. During the first quarter of 2021, the first commercial sale of Evrysdi in the EU triggered a $20 million milestone payment to PTC, which was reported as collaboration revenue.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">U.S. GAAP (generally accepted accounting principles) R&amp;D expenses were $134.5 million for the first quarter of 2021, compared to $90.1 million for the first quarter of 2020. The increase in R&amp;D expenses reflects costs associated with increased investment in research programs, and advancement of the clinical pipeline.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Non-GAAP R&amp;D expenses were $120.8 million for the first quarter of 2021, excluding $13.7 million in non-cash, stock-based compensation expense, compared to $81.9 million for the first quarter of 2020, excluding $8.2 million in non-cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">GAAP SG&amp;A expenses were $61.1 million for the first quarter of 2021, compared to $58.2 million for the first quarter of 2020.</font><font style="color:#000000;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> </font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The increase in SG&amp;A expenses was associated with entering into a long-term lease for the Hopewell facility that commenced on July 1, 2020. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Non-GAAP SG&amp;A expenses were $49.1 million for the first quarter of 2021, excluding $12.0 million in non-cash, stock-based compensation expense, compared to $51.2 million for the first quarter of 2020, excluding $7.0 million in non-cash, stock-based compensation expense.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Change in the fair value of deferred and contingent consideration was $0.1 million for the first quarter of 2021, compared to $0.9 million for the first quarter of 2020. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC&#8217;s acquisition of Agilis, which closed in August 2018</font><i style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.28;text-align:left;">.</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Net loss was $128.6 million for the first quarter of 2021, compared to net loss of $112.7 million for the first quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Cash, cash equivalents and marketable securities was $988.4 million at March 31, 2021, compared to $1.1 billion at December 31, 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Shares issued and outstanding as of March 31, 2021 were 70,405,905.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:15.2pt;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Reaffirms Full Year 2021 Guidance as Follows:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC anticipates net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC anticipates GAAP R&amp;D and SG&amp;A expense for the full year 2021 to be between $825 and $855 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expense for the full year 2021 to be between $725 and $755 million, excluding estimated non-cash, stock-based compensation expense of $100 million.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results and financial guidance of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the Company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><a name="_Hlk70065754"></a><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:76.49%;" align="center"><tr><td colspan="9" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;">(In thousands, except share and per share data)</p></td></tr><tr style="height:20pt;"><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:20pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:20pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="7" style="vertical-align:bottom;width:34.07%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:20pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Three Months Ended March 31,</b></p></div></div></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2021</b></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2020</b></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Revenues:</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Net product revenue</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:bottom;width:14.14%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">91,280</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:bottom;width:13.03%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">68,196</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Collaboration and grant revenue</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:14.14%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">20,007</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.03%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">63</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Royalty revenue</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">6,655</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">-</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Total revenues</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">117,942</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">68,259</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Operating expenses:</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;white-space:pre-wrap;">   Cost of product sales</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:15.68%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">9,104</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:14.56%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">4,085</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Amortization of acquired intangible asset</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">11,278</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">7,494</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt -4.5pt;"><font style="line-height:1.07;white-space:pre-wrap;">  Research and development (1)</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">134,513</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">90,107</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Selling, general and administrative (2)</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">61,095</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">58,209</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="font-size:11pt;line-height:1.07;white-space:pre-wrap;">  </font><font style="line-height:1.07;">Change in FV of deferred &amp; contingent</font><font style="font-size:11pt;line-height:1.07;"> consideration </font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">100</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">900</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Total operating expenses</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">216,090</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">161,250</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Loss from operations</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(98,148</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(92,991</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Interest expense, net</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(19,159</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(5,642</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Other expense, net</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(10,884</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(13,832</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Loss before income tax expense</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(128,191</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(112,465</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Income tax expense</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(451</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(222</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Net loss attributable to common stockholders</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:bottom;width:14.14%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(128,642</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;border-bottom:3px double transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:bottom;width:13.03%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(112,687</font></p></div></div></td><td style="vertical-align:bottom;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Weighted-average shares outstanding:</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 9pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Basic and diluted (in shares)</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:15.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">70,188,602</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:14.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">62,389,158</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Net loss per share&#8212;basic &amp; diluted (in dollars per share)</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:14.14%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(1.83</font></p></div></div></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:13.03%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">(1.81</font></p></div></div></td><td style="vertical-align:middle;width:1.07%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">)</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;border-top:3px double #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;border-top:3px double #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">(1) Research and development reconciliation</b></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">GAAP research and development</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:14.14%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">134,513</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:13.03%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">90,107</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Less: share-based compensation expense</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">13,725</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">8,179</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Non-GAAP research and development</b></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:14.14%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">120,788</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:13.03%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">81,928</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">(2) Selling, general and administrative reconciliation</b></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">GAAP selling, general and administrative</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:14.14%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">61,095</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:13.03%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">58,209</font></p></div></div></td><td style="vertical-align:top;width:1.07%;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Less: share-based compensation expense</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:15.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">11,982</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:14.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">7,041</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:14.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:24.85pt;"><td style="vertical-align:middle;width:64.24%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Non-GAAP selling, general and administrative</b></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:14.14%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">49,113</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:13.03%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">51,168</font></p></div></div></td><td style="vertical-align:top;width:1.07%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:24.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:26pt;"><td style="vertical-align:top;width:64.24%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15.64%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:9pt;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-2.884613%;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:105.76%;" align="center"><tr><td colspan="9" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Summary Consolidated Balance Sheets</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;">(in thousands, except share data)</p></td></tr><tr style="height:26pt;"><td style="vertical-align:top;width:60.6%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;"><a name="New_Section"></a></font><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">March 31, 2021</b></p></div></div></td><td style="vertical-align:bottom;width:0.8%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:19.39%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:26pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">December 31, 2020</b></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Cash, cash equivalents and marketable securities</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:16.49%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">988,406</font></p></div></div></td><td style="vertical-align:top;width:0.77%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:15.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">1,103,650</font></p></div></div></td><td style="vertical-align:top;width:2.39%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Total Assets</b></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:16.49%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2,111,941</b></p></div></div></td><td style="vertical-align:top;width:0.77%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:15.88%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2,208,278</b></p></div></div></td><td style="vertical-align:top;width:2.39%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:18.38%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:19.39%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Total debt</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">430,038</font></p></div></div></td><td style="vertical-align:top;width:0.77%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">$</font></p></div></div></td><td style="vertical-align:middle;width:15.88%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">309,145</font></p></div></div></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Total liability for sale of future royalties</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;white-space:pre-wrap;">                  694,984                   694,984</font></p></div></div></td><td style="vertical-align:top;width:0.77%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.07;">    </font><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.88%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;white-space:pre-wrap;">                 679,762              679,762</font></p></div></div></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">Total deferred revenue</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:18.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">1,887</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:17%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><font style="line-height:1.07;">4,151</font></p></div></div></td><td style="vertical-align:top;width:2.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Total liabilities</b></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:16.49%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">1,819,365</b></p></div></div></td><td style="vertical-align:top;width:0.77%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:15.88%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">1,726,296</b></p></div></div></td><td style="vertical-align:top;width:2.39%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:18.38%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:19.39%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:55.5pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;">Total stockholders&#39; equity (70,405,905 and 69,718,096 common shares issued and outstanding at March 31, 2021 and December 31, 2020 respectively)</p></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;">292,576</p></td><td style="vertical-align:top;width:0.77%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:1.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;">481,982</p></td><td style="vertical-align:top;width:2.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.6%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">Total liabilities and stockholders&#39; equity</b></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:16.49%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2,111,941</b></p></div></div></td><td style="vertical-align:top;width:0.77%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">$</b></p></div></div></td><td style="vertical-align:middle;width:15.88%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;line-height:1.07;">2,208,278</b></p></div></div></td><td style="vertical-align:top;width:2.39%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:bottom;width:60.6%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.38%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.8%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:19.39%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:2pt 0pt 2pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:2pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:2pt;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 7pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 7pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.23;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc. </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.23;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2021 R&amp;D and SG&amp;A Expense</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.23;text-align:center;margin:0pt 0pt 8pt 0pt;">(In thousands)</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7617531%;width:103.52%;" align="center"><tr style="height:15pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;"><font style="line-height:0.83;">Low End of Range</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:3.75pt 0pt 1.5pt 0pt;"><font style="line-height:0.83;">High End of Range</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.97%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">Projected GAAP R&amp;D and SG&amp;A Expense</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">$</font></p></div></div></td><td style="vertical-align:middle;width:15.58%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">825,000&#160;</font></p></div></div></td><td style="vertical-align:middle;width:1.01%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">$</font></p></div></div></td><td style="vertical-align:middle;width:15.58%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">855,000&#160;</font></p></div></div></td><td style="vertical-align:middle;width:1.01%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.97%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">Less: projected non-cash, stock-based compensation expense</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:17.28%;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">100,000&#160;</font></p></div></div></td><td style="vertical-align:middle;width:1.01%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:17.28%;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="line-height:0.83;">100,000&#160;</font></p></div></div></td><td style="vertical-align:middle;width:1.01%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:60.97%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;line-height:0.83;">Projected non-GAAP R&amp;D and SG&amp;A expense</b></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;line-height:0.83;">$</b></p></div></div></td><td style="vertical-align:middle;width:15.58%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;line-height:0.83;">725,000&#160;</b></p></div></div></td><td style="vertical-align:middle;width:1.01%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:1.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 2.65pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;line-height:0.83;">$</b></p></div></div></td><td style="vertical-align:middle;width:15.58%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;line-height:0.83;">755,000&#160;</b></p></div></div></td><td style="vertical-align:middle;width:1.01%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0.99;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.29%;border-top:3pt double #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.29%;border-top:3pt double #000000;margin:0pt;padding:0pt;"><div style="height:15pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.43;margin:3pt 0pt 8pt 0pt;"><font style="line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#8217;s Conference Call and Webcast Reminder: &#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC will host a conference call to discuss the first quarter of 2021 corporate updates and financial results today at 4:30 pm ET and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 4292410. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#8217;Keefe</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Jane Baj</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9167</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jbaj@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Reaffirms Full Year 2021 Guidance as Follows&quot;, including with respect to (i) 2021 net product revenue guidance and (ii) 2021 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; expectations with respect to PTC&#39;s gene therapy platform, including any regulatory submissions and manufacturing capabilities; advancement of PTC&#39;s joint collaboration program in SMA, including the commercialization of any products therein or royalty or milestone payments; PTC&#39;s expectations with respect to the licensing, regulatory submissions and commercialization of its other products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: expectations with respect to the COVID-19 pandemic and related response measures and their effects on PTC&#39;s business, operations, clinical trials, regulatory submissions and approvals, and PTC&#39;s collaborators, contract research organizations, suppliers and manufacturers; the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC&#39;s gene therapy platform, including any regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of ongoing studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any regulatory submissions and commercialization with respect to Evrysdi; PTC&#39;s ability to utilize the dystrophin results from Study 045 and the totality of existing clinical and real-world data or, alternatively, data from Study 041 to support a marketing approval for Translarna for the treatment of nmDMD in the United States; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC&#39;s ability to fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi&#8482; and Waylivra&#8482;; the enrollment, conduct and results of PTC&#39;s PTC299 clinical trial for COVID-19; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Evrysdi, Tegsedi, Waylivra or PTC-AADC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.<br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ptct-20210504ex9919ca02a001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptct-20210504ex9919ca02a001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G *D# 2(  A$! Q$!_\0
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M )$*Z_ZZQ?\ H0KYY[U]#?%O_D0KK_KK%_Z$*^>>];T?A ^HO!G_ ")FC_\
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MO+ .()+N/:&=<[!D$9'^>M>8_P#"D;[.?[9MO^_+?XUM1G%1U&U9V/1/A_\
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M20Z7I]O=/=0V-M'</G=,D*AVSUR0,FK=%%P&NB2(R.JLC#!5AD$53_L32O\
MH&67_@.G^%7J*32>Y49RC\+L41HNE Y&F6>?^N"_X5;:*-U"NBL 00",X(Z4
M^BA)+8)3E+XG<ABM;>!BT,$4;'C*( ?TJ:BBF2%%%% !1110 4444 %%%% !
>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ptct-20210504.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2021 7:55:47 PM-->
<!--Modified on: 5/4/2021 7:55:47 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20210504" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20210504">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20210504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20210504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ptct-20210504_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2021 7:55:47 PM-->
<!--Modified on: 5/4/2021 7:55:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ptct-20210504_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/4/2021 7:55:47 PM-->
<!--Modified on: 5/4/2021 7:55:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptct-20210504.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637557549473226348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637557549473226348" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637557549473236356" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637557549473236356" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637557549473236356" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637557549473236356" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637557549473236356" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637557549473236356" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637557549473236356" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637557549473236356" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637557549473236356" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637557549473236356" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637557549473236356" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_637557549473236356" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_637557549473236356" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637557549473236356" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637557549473236356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637557549473236356" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637557549473246339" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637557549473246339" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637557549473246339" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637557549473246339" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637557549473246339" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637557549473246339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637557549473246339" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ptct-20210504x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20210504.xsd" xlink:type="simple"/>
    <context id="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_hvxiUsZoi0yLmHJ1MxmXiQ_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_XwA0o76Dgk-CxNnYvctUYQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_lzL2h9TWUEm8hxyEovJcig">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_7t0mWQXXlEykqLU0U418Kw">2021-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_7GZgWUYXGkCYsHTTuaJ-zw">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_fFLHK7B6JUC7j7TDsHn_4A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_kyw_hDQNLEuESNNYL5o0TA_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_iC7onP3bMkyfglZfj9Tveg_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_iEdivVLIBEa0I6_TZStJ8A_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_HKpNm0mI2EetlaK9jIfXUA">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_Dc12wex61UW_HiH6zFwLOQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_LDtiFDk4QUaDSRGM_983pQ_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_-DEPeNK_MkGXked7N-Y2xQ">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_MRVbwu1G-UKKz4moZrjeFw">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_98rgxFR0j06oWmIpB75hOA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_09Zp2f0NzEG2vWZWB2V42g">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_i9pgC4iVW0OPmzE3WJMU9g">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_bhlkJ-xcBEKYEBNGm_e8ig">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_iQ-xtfmqcE2u5TetlNgPnQ_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_RcPUcIO0_0Ses93Lb_3NCQ_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Tc_eC0ZZOI3Z0ifJJ375MhDyg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA"
      id="Narr_ftZPt3nRo0ChTVt4-XY4Hg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139915847874536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" ":@*12HZ8.<$ $  !K$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8T7+B-A2&K[=/H6%ZT<Z06'9((#N$&4)(E^XFZP:V.]-.+X0M@R:VY$IR
M"&_?(T-L.C7'I#>Q9:1?G\Z1?DD9;I1^-FO.+7G-4FEN.FMK\X^>9Z(USY@Y
M5SF7\$NB=,8L%/7*,[GF+"X;9:D74'KE94S(SFA8?@OU:*@*FPK)0TU,D65,
M;V]YJC8W';_S]N%)K-;6??!&PYRM^)S;;WFHH>15*K'(N#1"2:)Y<M,9^Q]O
M@YYK4-;X7?"-.7@G;BA+I9Y=81;?=*@CXBF/K)-@\'CA$YZF3@DX_MZ+=JH^
M7</#]S?U^W+P,)@E,WRBTN\BMNN;SJ!#8IZP(K5/:O.)[P=TZ?0BE9KR+]GL
MZO9Z'1(5QJILWQ@(,B%W3_:Z#\1A _](@V#?("BY=QV5E'?,LM%0JPW1KC:H
MN9=RJ&5K@!/2965N-?PJH)T=W:FH@"!;PF1,IM(*NR4SN<LV1&WH6>C$5?6B
MO>#M3C X(OC MH3VNB2@@?_OUAZ@57Q!Q1>4<A?_CX_\.5X:JR&W?R&=752=
M792=]=HZ6VQSWC1TO/G@[#,"T:L@>J=!A%P+Y08=$TAM(P^NY%+1Z_[PX4-+
M+BXKLDM4;Q_^>Y%R\EAD2ZZ;F' -2OVSB\OKJVN$YZKBN3J%YXFOA)L#$+)'
MEC7&"=<)%Q.R^#1]&H?3;XO99-XEL\?).0+8KP#[IP#.9*1TKG0Y8[MD;B&;
M1&DR486T>@O/N)$:%[^;(H2#BG!P"N&"O9)9#)-.)"+:+:SC"<85:>_LHN=?
M70[Z"-YUA7=]"MXXCC4WIOOV0KY /?)5-D8-5_0IA7COLL%=!K1%.'U:VRA]
M%^G$E2#'"[5I-E%<;@X;Z)J$*6RKB>!IC#$>6+W_+L9J(H9:O0@9-8:S1?/Q
M5PRM=GD_>!=:J(QE*?E#Y$=71XLB[=,!Q=CJ3<'';;U,Y1B./,=1<(%K.L!
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M<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( )J
MI%(D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.U
MD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.
MGV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S
M9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H
M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
M" ":@*1299!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.
MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>
MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X
MJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/0
M8&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]
MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD
MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_
MYHOA/UY_ 5!+ 0(4 Q0    ( )J I%('04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ FH"D4AI7SRGO
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ FH"D4IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ":@*12HZ8.<$ $  !K$
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ FH"D4I^@&_"Q @  X@P   T              ( !A P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ":@*12EXJ[',     3 @  "P
M        @ %@#P  7W)E;',O+G)E;'-02P$"% ,4    " ":@*12'#AEZC\!
M   \ @  #P              @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ FH"D4B0>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ FH"D4F60>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ptct-20210504x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ptct-20210504x8k.htm">ptct-20210504x8k.htm</File>
    <File>ptct-20210504.xsd</File>
    <File>ptct-20210504_lab.xml</File>
    <File>ptct-20210504_pre.xml</File>
    <File>ptct-20210504ex9919ca02a.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptct-20210504x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ptct-20210504x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20210504_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20210504_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20210504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20210504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20210504x8k.htm",
      "contextRef": "Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20210504x8k.htm",
      "contextRef": "Duration_5_4_2021_To_5_4_2021_L7hVQ11VN0KhOK9XCDliKA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001070081-21-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-21-000015-xbrl.zip
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M1"!W$9]#N"YQ(-?>#N5O4U:*5Y76#V;QZQKY,99YU 8?/U'Y\!=02P,$%
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M\"$-R BX17!XZJF\!Q??%G=6Q,8IYE[&W%]71>*1CHF/^UA0?OT40.8LRTS
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M6<0#)U^FJ&1/R=[V9"]=P?*0X+4V%+QF[[F"EUM(]9P5,TJ6E"SM0);DNI9
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MGSF9AP@C;MU, +RS(/SEI];@5!Q[%LW(8<_0VD9'&Q@=<?I9=Z#US+YF#+K
MY-,I]^0)P2%QPC!FMKB'QU$8P0<8(J$1^50XSE+<<>^X/ )-^'B$[2US9[F3
MADO''77ES/(/5EGM!NU\CMX\>8SKGM:U^T&N[T$W!TVMT^NN,?:GGUOU8L0M
MR;?<"@A2LO_B[%&&[*][O%"59;_=-[5!O_DDV7]^D4U]9%\5M%0!5#^OH$4@
MO57 4E6[U,D"J6S<G@JMJG:I,I'5J38J&Z="R!401&5?%<55M<O>$5F=:J/L
MZXZK70I.;)6J7907JR(-U:31X\GT KT>+FI1%%-2I6BT@50]6**B*+:32I3C
MB +R2Z]O86@PC#5AT[R1YK+I><E33=JMU3L[/3*J2HWCH1VJTG'T2N8[-9 '
M!_(TSEKM,QZ\^WI]3JXG#!0?BZ$;H4:N/$LGF<-8]?Y_8Q;W+* #1>V+.R3_
M=G;VE42<?.9>0WS^&O _F!4QF[R/79?\E]% 5H!]^X5._=,+D1_\_IOX<D8N
M?_C,"UF5)N#PRB/1A,?0O!W*HC2A>(46GMLBX7Z#.76I'[*3]$.^(UUH+NG#
ME/Z >^&]7JII&RX;12<-4^]US5ZG9?Z<6;"6WFF"$2.BMW\_D-T]*,/K'+SH
MEJG5,=^[CKT7(97>?-'=-%\#&9[N.S97H]RFWNVD>$]\W'\J@:H8K%:9+;V7
M3HBI=QZ'5.#TM>#WC_R.7&*=\(A\H]ZXC!WZE"PI6:HZE80L/4]R/L"7]46G
MI"*ZU6#A9:A8T8Q2GKQ/<#,3RL[!LL#.#T/DDM1E93-'KT&;KI7?[VU(I"P@
MIZ3R65)9TC%HG7Z%A:W*A%N5H'\Z)?O-C@;S_,M/9M<H1S:-334H,>;&7]%X
MRY%9Y4\H"Z@LH+* =25<B1:PHRQ@-6F\8PNHP@(UH' :*F5A>$+\+#C@<:]A
MT7"B$;&PKC&D(</(W!0C S(5QTJ.$B@0M).@ZKIG)D"O'BW#44)7KNF$GF[!
M="K;6#W;J!2C4HQ[+U-*,>X!$973\'HIO-YBM'N912^MS%N:760+!7C*-E;6
M-JK(:>VDL(R%P"J(NGW \R2B]HI)Q6<26,53ZPF-E%U4=E$)F;*+]:/AUNQB
M1]G%"I*['B$#M5:I&F93H9=:K*_(*4;<L&UA<R!%,24X>T\&)3BUHMANMK(0
M^T"DJZVV@WAVL%G"'W$8.:/94S;ER&/SW0W$>/9 ADL[<18XU'VL"\6M":ZY
M36<X2K-W&I)S[HU8P#R+$1B0*W(>_V%#BX81^<:FC@=*X(0LN"K;FI"<5EE&
MNG4'+;>/N'-@.!,.XZ"@ K-16CC*B!/;":TX#$DT863D!'#;GS$-(A;@XD&Q
M#X/% Y\'X(>0V+?AC]RQ?>1XU+.@ W@F3^Q&T ).*)[DTSYI&<2?DLMK<:=%
M/3)DA%H6@_<,9_!*F"%O3 [[O=X1:1FMQJ!I=LFAS:<,R&\=$1Z0PT&O=40&
MK4ZC;W::Y-#!%<6>J%VC[A&\_I81($N,_?$#!YZ P> @P@BZCYW'+U9*2S_@
MMXXX:@@O^S0,+6XSTFX.FFW3T,D9<:%%#?X?1LQK<,^=D;N$_FE;"Y-7&!>S
M"??$;8YW"Z. _DC%S;V0A'ADD=S^ N\05&%#4-J,K%*!D\PA&E+K9ASPV+-Q
M]P@>G*2VQW(9#=!F34Z+/^1VZ2DX=^E.$NDFD<A?^<TE3-Q<(D4AC4#R8^&:
ML(+2V(U90UHK.@+"G%#WCL["Q/#TNGI['C]+=O):L%^XPT7.3"76L]"1]%JA
M)X_9Q=RL++YBV9/;%^%'-?'ZX@RR=7=WI_N1-72X;O$I\FW*I0'S79"_/.,+
MT4<6O:6.*W8CH3X(P@]G"F(,#![=<= ,<0 2C404!:(NR[-J)C]94X$U@:G+
MN!T?H=Y,G-D09EP] O8''0#Z((3/+N";5/*P0;WZUO%)=F7.!J_2D)X->1R1
MY3L5[=!4EBAG.!8'A(*$EH/ZOF$'P/.>1L8N'X+% ^GS)S284DN,%:XD8@#,
M#L9T+AUH7!'ASS1BLUOF<G_*H%?"*O+IE 5H0)V_LLV1+!@?MN>BD1P):Q,Y
M%(LRILQV+!@\&FI0 ]*<,9!(CXT<87S!J$706_A\YT03$M! O%_HX%!'^B1"
M*D]>F>$C<CSPMGQO&+9NQU:$I_5)7(#61W92O%U,1YA8.C$BQX/9"O@P#N7H
M0"'#6YV1 UWW'9\AW81.2:.;0@'G1B4/! S I(>A> _/QI@ ![@RA-<UP Q9
M+L4+8'[$VT.A;^;#GX!6H] ZV.?8F[)(O@:HY#%FZ\BE /?R:BN,$-Z,9V*\
MG+A J@ ,',&)A=\XZ"[!"2!1CB4J8,!M#)GH=,(2\PF$N1@%H) #F,$8:  -
M@B%RICBQM]2-I7;$IK,>B\'#1*/-IS<L.0<'>HI]H8%'IAP:HJF<:02T-(7W
MH[J)2!R2>X9!0C2A>?%WF-#WP*Q#SF\T_'(-+((*'Y[['VCP5X=KLA,>^>AX
M-\R^\I22WBLE_1YX[A-RT967B!\ H:UKYY<9ZU6"P,-JC>\9!NF?,]=AY$OB
MK?Z3L1&K'*L^8WC_UP1WS^BC+V@TC.[ W*?!W? ;I-?_S)6STJP5H&AIVN83
M@ NZ-YKF'Q2 VJ_TC\K1JPSU,C";C8'9[>W3X/X8TC^4;JD6.<M$;7<TL!L?
M ;AC!.5[!'Z*<'FVC]VVPJW7$P?#M>C/!4PZ,;C-+74\X<2)P;K)8,-LL,*C
M=:1+/674PU_!F41'[BNXHAB:_LZL.)#GB7Z$/V/IK7YC"';)F26"N.9@T-')
MF>OFFTY>#WZJ>(&3=4Q+7#+P>+W\ ] 0W 7P$ES!$;4B\)P"]D#G-6C8<N,L
M]NS, 7CJXMK@I]KB58Q,&!6W_O)GS*-3C$1\8W0T<H)IN+A!\F^Q8U,,1U/X
M2?AZH7PJ_TH9#&"ASV 2P!<]=([DTQZ+4D<??K]E'GBFXZQ%< 8/G?16L1H$
M+ZVU-"1K14N.=LVF+F!CF"-,DLJP0BP<9'S,BF2H'%U;8)@T9"]Z+=U[X?>N
M'A:V)QN"V8S VY8LD@942(2LF9XU"TTP>%42%I71$+C9IA'5L).Q2X&^,Q+&
MPR0>(9_$]\%GEO?8@9+@28>GA6'<Z]X\^C)F8& C$2B;X6 CY(;\R#",]$ ?
MIM2+D>V V^%FB_K90;JGA-JW..\B(@/CF;_T#^[ );'G]!!3.0GOC0,Z1;;_
M_NELD4N7AJ>P:UEL",? X&',=/ 9=7$.,7[CHN_E88YE)JA^FNO'@W.$KW4=
M"U@(.O$@'99V#B,JDB19%Q,N$BQNP1='I*_R'4HC/UK*C-QG0<J*R:5YIBO-
M(&0_)7*#;)LMG[)XB(/&=^.(^!"OBW@9=!*H1\>"0#KY(CK[@-:;TAF&W$%!
MB,@3M#V<B3:Q0 #>*84]E;94].5?%"--?DRN4&C$<GQHO7A]R,"WO%VXB'FX
MZ;U;)?F*US OY]G%:]#QXH4(; E;>-#GD8ANNL7+F&A8N,)C=^$%UOU+X639
M;? "H$]Z54@_Z 87-"B,!<T04EI72;C:)^&>4:!28U2ZK>Q'FBD ,S-/\(.2
M8X' +H@00-=3:X*:(\51('Y)U@*-(L/WN#,R"O@4CT<(62IRF!X)B#/UW42E
M/: "G0C:ND&#B^D8V1%AB<@M#1PF[7;@A#=2V<?0LP#A7"0,?-ZD80<$SR$^
MX">/FZ+S+_^^NFB8 S!D ,ZF@/8D!)!-I%  \6@(IB!,%;X#J@7F ,T/V*7Y
M7 [C$!,=T*N\B5G )P]:/9&[O15WX==YTW.[S@-L$\@=4('J0H;Y6ICN,8#F
MO]*7AK&/<Q\L @H!8X3-BB,PL2)AXP>8H!ECJTE21,Z",QW&02BAAL?&/'+R
M4PDX.@#32P,@$.  Z%:*X9(N9R::!TLLM,PR(?8MY*7$W6@4B]FJQ#&0)GEG
M."PS7WFZK 9G&1Z8/S?'%2 +2"^\)4OH)8A&N"(V9AQ=/G:L<.$5\$G"U_O-
MYZ13@-MY_K' 9<(F4@!M<^B6@BPTGF-\/(5R<[HDT(0/772UA$@)097\P[P
M6%*^"II!ZFHI@!:E0M ?[HVY%':!QG,>$*#1!:B*CR+2@B=M,6Y-J)^"2M"2
MXA_9FNAHHI*8*(M /A-M *,$ GGE,[+SMR>P^ F<<!^-+G+=Y6TP"VWG='D2
M-HX<P<<B83S#?*./SFXZ5T*!?H=QS8C1[F2$CGA$4\>%_0"'5'!<JD[D9%,7
M:TEQ#L"S@2D (KA)%14,'9/2>+WP A-[A J"!U@P!@;FAHFF4RX7@GPMEZ9
M2^*KZ$^:C<4.>=.+3Q>I8/[N.<@A(G81KIB#*>IL^"=X/O?2&!1WD /Y3WKQ
M90Q3R<![OP0FY*C!S^!><GAY>794\"4G+/'T<\]\RE+39R #U@P>^W1V!$P#
M$S@5U^$MB1M /4_:28_=82YX9KDI#V*;B4PWT$Z1(76E_2P,ICC09/[#K$6X
M.8Q!D1=N6S&5(^!E+2WED>H:L#R6^PC&S>P;#$?\S<EDQ@0:2A8\R3%K#:V9
M_<84U,%$N.>81Q:'$Z&0H\-3L&'K4TFFIR4$@ E/WX'V$; P!;\$&#M"=Q ]
MKKN) Q,@JS) KD0F/E$_2;U BO;ME0R4\L7EV2-F8J4'?,W&H(X=@'CM?E,Z
M%/^A,]>Y#6AR;:4&7%2 <^+!I^9@L#B/.',I!CD%MV7LX9C!B\N@1 HT%GWW
M#'^ "8%7@T:9:<F<:(0EL@"DY&B:\(6B6#'3;]A?@=%!6*T)'A\A>#VB/W)A
M#Y?>S=&*A!5!5AN*+5LB(B&Z T1RL/@LJ7<@N!OA@N;,V:W"U#S%E9]7: A=
M15%>L$ #9"B =O/J7BAYF,$5(H1;)(:CF0PI9#R6MU&H!,*T2$[&,2FT**UM
M6M^QINV6LQ3&HY$CRHUFQ2G ?1R1;W@<6,G\8N.Y[O*A4)W49G_&& M-@ 6\
MH@"-LG[!7T"&3!8$"M2<OY+ 4W@ZB><E5H[Z#E@<>1'X S'O/,J!HT*4EU03
MI]%4ECCBWU#SO9?W)+YXKB9V/M8I%X6,>'P0^9<L0P:]]8T):X1%+!C--8W&
MO\2+SZ3:O?_S/S4$!W<,:Q=#8;[3RF4IV^@*8(_27H\<U&/24P%5*>["OTX>
MP$N^AUMA:C*8"VCE\EPG_^6QB +'P5AB(0N^C6)9604*#-D&*RF%$D_>6G:!
MS>X<Q+-D^"(<6*R#DQ)2P)HB3BAF)Z_#I,^6,,E*;)IBCI5!/S"/F8X0E5W)
MJSQ.QL _\":66N)<\%)6LR*?81&:<"H2^+'LY2A:\"SP8N#@+UKBM-PR69.6
MZYDPLJ)<#8B?5\MSBZB1R^G(I7_A!PD+M=2J:)DM(=)9:IR=79S7ET^N)P_E
M17*9ER22'#",#Z#LSZ7NUF%WZ$G#S-),X:(LR\_WLDF)9TQL#G3W>(+LL:I.
M4 VPEX#<OFP"[=ZMK.2;)<*YNK_P' BUBQ"A&!C!=G*&4F0PM'GZ I51&$_]
MQ$RFH=74]_U#*L)0L)54,I836/$47NVAQN>6%0?"8L@J[4=F@/VP&)"/XI4_
M8R>0  OLM?YVB"NJ)#-M3-8-EG-M,XSZ_)CI+7?LQT*FQT-NS^#/))JZ[_X_
M4$L#!!0    ( )J I%);KG/5L!8  +&P   4    <'1C="TR,#(Q,#4P-'@X
M:RYH=&WM/>M7XKZVW\]:]W_(]=SS&V<M"VTI3V<\"Q$5'^@ CHY?NM(VI1U*
MTVF+P/SU=R=MH8 ZHN)C9-8:Z2--=O8[.SO)E_^.^@ZZ(7Y@4_?K)RDC?D+$
MU:EAN]VOGRXZ^T+ITW]W_H7@'_^#T)?_%01D7^VV3I!!]4&?N"'2?8)#8J"A
M'5H5U*&>AUUT2GS?=ARTZ]M&E\2?E#.%3+$HY3**J.1S2!!VTM7NX@!JH6XE
M+BUEI/DBM;@I5BB?5;*R*$NH6,GG*XJ"SD_GBT?UG-B:C_UQTL\*5"Q.P"@L
MM!%]U";^C:T3=$0UU-BK()%@HU@J%(4"E@Q!,>6"4#((AC]2J:R)AI@W2*HF
M^/EBA8!<0+ ;5 QB?]VPPM"K9+,CS7<R =$S77J3A1>L$Z(@2D).VHB*3XH.
MA\/,,)>A?C<KE<OE[(A5&1>J.+;;FRG)*V9E95',9=EK#3":%!\ME)^IF;V=
M%(6*C' 6X+C>?#9Z.2EZ*[!04,I>G9ZT=8OTL6"[08A=?0**/0H%0,#,EPE"
M;!<@(8P$V=#';F!2OX]#(!M4*N4%L31%4\4+]7"F$GB@V32CTS[G##$O*JDV
M;T?6GQJ4!;DPK>0NA$NY5$5)<9^8=Q*HD(6W:83;]]!R@L"=+Q;PX<Z7/@DQ
M8L4%\FM@WWS=T*D;@BP*X=@#-,=W7S=",@JS$=-D=[Z$=NB0G2_9Y#>J2Z/&
M>.>+8=^@(!P[Y.M&'_M=VQ5"ZE5RHA=N0ZM9>#U3QK #S\'CBDM=P@K8HPJK
MC?C1I6T8Q.674* ):L*W]0BJ4=AB6-D;^!S):EY55$8KM4.GUR=%Z_LW2?K>
M%(^ML^/R56W/L8^K&\C%?=8VL2MU%SHQKD$G?>PT7(.,CLEX ]G&UXV.KEHW
M(_LBN*:V.#[I'QY)IZ/^E?U-E55I8T<$WA2+HEB2OF1GX%LEN%50E 93EOL.
M[D[ O!I615HL['5[0FW4='_<Z.'%CV]JCH%I8B<@"Q!F9Y$++$1\4-@DV/G"
M!+@2<($#D!$7Z(K%69#)B9 (1&84&!OQ:\8M7S<"N^\YC+>RLW5$S:7;X+<!
M'?C\CG-M)483[].CT)141#A)DSO;8/>F37S$ 2*W:HM:XWB6HO,?[R2/9FOW
M )W42.Y N/QP#PS+#H-3$$'JE>2[Z;L)F,8=19,WR7W22'8&40E6)VC,IF1G
M0<[Z>"0,;0,,JR2*_]GVL,%LL^ 0,X0GF5Q^^LRWN];T(0UL1@EHR &2W' A
M3=6K.P3[%8V&UO9\$[=]Z27?F= )P<1]VQE7/G7L/@E0DPQ1B_:Q^VDK>@*_
M 73=_+3-2P?V;P)5@R))((5F0]JO2*E'3-FP>X8A 3MVUZWH0#+B;VO4!]1,
MOLE 12B@CFV@?XO\7U*"ZZM;7D?JK!)KLH Y)^G.</!D>,GOAH1C4:..$7\X
M:9F5N;$#6[,=X*18#*'*?_Y=DL7<]I<LJQI(Z#T7NA9Q\9"NY.'EXR''7(Y5
M29>UD@0R"W]$53%D7=7,,E9SFE&0L5P@!<-D"@._5%^UQ8Y*Q=N(MK%ST6QT
MZGNHW:EVZNTO6>WU25)^$DG>'(+;]=I%J]%IU-NHVMQ#]:O:8;5Y4$>UL]/3
M1KO=.&NNL1XUOQS29[%\66T?-IH'G;/F%MK+U#)(%O-*>8W9F"^?@MK]L];I
M/_^6"N(V1^?JW+Z]>(C<X5XYTZQ-[/NJ\_M$MLJ=RXMZOV2-QG5Z<Z3;W3\
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MN/%,8Y"RD^62WQWMM\2?8H%>]AO>;C%OG57GNJQ3A_J59%>7&42W29<2=-%
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MAA\K[#L[_P]02P$"% ,4    " ":@*12?ZO-6%@#  #F"P  $0
M    @ $     <'1C="TR,#(Q,#4P-"YX<V102P$"% ,4    " ":@*128+1Y
MBW0%  !\/   %0              @ &' P  <'1C="TR,#(Q,#4P-%]L86(N
M>&UL4$L! A0#%     @ FH"D4FP%S\][!   ?28  !4              ( !
M+@D  '!T8W0M,C R,3 U,#1?<')E+GAM;%!+ 0(4 Q0    ( )J I%*I</&:
MQS(  ,4Z P <              "  =P-  !P=&-T+3(P,C$P-3 T97@Y.3$Y
M8V$P,F$N:'1M4$L! A0#%     @ FH"D4ENN<]6P%@  L;   !0
M     ( !W4   '!T8W0M,C R,3 U,#1X.&LN:'1M4$L%!@     %  4 40$
' +]7      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
